US Material Events SEC 8-K Filings — May 13, 2026

13-05-2026

GROOVY COMPANY, INC. (GROO) filed an 8-K on May 13, 2026, covering Items 4.01 (changes in certifying accountant), 5.02 (departure or election of directors/officers), 5.03 (amendment to Articles of Incorporation), 8.01 (other events), and 9.01 (exhibits). Exhibit 3.1 details the Amendment to the Articles of Incorporation. No financial metrics or performance changes were disclosed.

• · Filing Items: 4.01 (Accountant Changes), 5.02 (Officer/Director Changes), 5.03 (Articles Amendment), 8.01 (Other Events), 9.01 (Exhibits)
• · Subcategory: Accountant Changes

13-05-2026

At the annual stockholders’ meeting on May 11, 2026, MDU Resources Group, Inc. shareholders elected all eight director nominees, approved on an advisory basis the compensation of named executive officers, approved the amended LTIP increasing available common shares by 6,564,000 to a total of 15,806,806 shares, and ratified Deloitte & Touche LLP as the independent auditors for fiscal 2026. On May 13, 2026, the Board adopted an updated 'Leading With Integrity Policy' clarifying provisions on AI, confidential information, conflicts of interest, and compliance. All proposals passed with strong majority support exceeding 90% in most cases.

• · Proposal 1 (Director Elections): Votes For ranged from 156,077,464 to 157,868,483; Against 382,487 to 1,772,995; Abstentions 196,056 to 892,983; Broker Non-Votes 25,924,878.
• · Proposal 2 (Advisory Vote on Exec Comp): For 155,483,583; Against 2,448,238; Abstentions 545,659; Broker Non-Votes 25,924,878.
• · Proposal 3 (LTIP Approval): For 154,587,051; Against 2,817,302; Abstentions 1,073,127; Broker Non-Votes 25,924,878.
• · Proposal 4 (Auditor Ratification): For 173,965,507; Against 10,089,093; Abstentions 347,758.
• · LTIP summary in proxy statement filed April 1, 2026; full LTIP as Exhibit 10.1.

13-05-2026

Jack in the Box Inc. reported Q2 FY2026 same-store sales decline of 3.8% YoY (systemwide), with total revenues down 4.3% to $254.3 million from $265.7 million, diluted EPS from continuing operations at $0.65 versus $1.09, Restaurant-Level Margin falling to 16.4% ($15.5 million) from 19.6% ($18.7 million), and Adjusted EBITDA decreasing to $51.3 million from $61.5 million. Franchise-Level Margin dropped to 37.9% ($60.5 million) from 40.0% ($68.3 million), though restaurant count remained flat at 2,128 with 9 openings and 9 closures. Management highlighted improving trends into Q3 under interim CEO Mark King, with updated FY2026 guidance for low single-digit SSS decline and Franchise-Level Margin of $265-275 million.

• · Del Taco losses from discontinued operations $2.3 million in Q2 FY2026 vs. $162.9 million prior year.
• · SG&A expense $26.4 million, down $1.8 million YoY.
• · FY2026 guidance: Company-Owned Restaurant Level Margin ~17%, SG&A $115-125 million, Adjusted EBITDA $225-235 million, restaurant count 2,050-2,100.
• · No share repurchases in Q2; dividend discontinued.
• · Actively pursuing refinancing of 2019-1 Class A-2-II Notes (repay Aug 2026) and 2022-1 Class A-2-I Notes (Feb 2027).

13-05-2026

Kevin M. Warsh resigned from the Board of Directors of United Parcel Service, Inc. (UPS) effective May 13, 2026, upon his confirmation by the U.S. Senate as Chairman of the Board of Governors of the Federal Reserve System. This resignation was automatic as previously disclosed in a Form 8-K filed on February 6, 2026, and was not due to any disagreement with the Company's operations, policies, or practices.

• · Resignation advised in prior Form 8-K on February 6, 2026

13-05-2026

Applied Optoelectronics, Inc. (AAOI) entered into a lease agreement dated May 8, 2026, with Hightower Phase I Owner, LLC for a 163,930 rentable square foot building (Hightower Business Park - Phase I – Building 1) at 6000 McHard Road, Houston, Texas 77053, plus an adjacent 3.34 acre unimproved Reserve Tract 4, for general industrial/warehouse and light manufacturing use over a 123-month term. Basic rent for the building is $0 for months 1-3, then escalates from $104,915.20 monthly ($0.64 per sq ft) in months 4-15 to $146,127.30 ($0.89 per sq ft) in months 112-123; Reserve Tract 4 rent starts at $6,680 monthly from month 4, rising to $9,303.99. No early performance metrics are available, but the lease includes a $391,613.18 security deposit and anticipated substantial completion around November 1, 2026.

• · Commencement Date: Earliest of Tenant occupancy for business, Substantial Completion of Work (per Exhibit D), or date Work would have been Substantially Completed absent Tenant Delays.
• · Estimated Delivery Date: November 1, 2026; Outside Delivery Date: January 1, 2027 (extended for Tenant Delays or Force Majeure).
• · Tenant’s Proportionate Share: 100%.
• · Permitted Use: General industrial/warehouse for light manufacturing, receiving, storing, shipping, and wholesale sales.
• · Exclusive rights: 24/7 use of loading facilities, trash removal area, and designated parking areas.

13-05-2026

On May 13, 2026, Las Vegas Sands Corp. completed a public offering of $500 million aggregate principal amount of 5.300% Senior Notes due 2031 and $500 million of 5.650% Senior Notes due 2033, issued under indentures with U.S. Bank Trust Company as trustee. The company plans to use net proceeds along with cash on hand to fully redeem its outstanding $1.0 billion 3.500% Senior Notes due August 2026, pay related fees, and for general corporate purposes. The new notes are unsecured senior obligations ranking equally with other unsubordinated debt but carry no subsidiary guarantees and feature higher interest rates than the redeemed notes.

• · 2031 Notes mature May 15, 2031; interest payable semi-annually on May 15 and November 15, commencing November 15, 2026.
• · 2033 Notes mature May 18, 2033; interest payable semi-annually on May 18 and November 18, commencing November 18, 2026.
• · Notes redeemable prior to par call dates (April 15, 2031 for 2031 Notes; March 18, 2033 for 2033 Notes) at greater of discounted present value or 100% principal plus accrued interest.
• · Indenture covenants limit liens, sale-leaseback transactions, and consolidations/mergers/disposals.

13-05-2026

HF Sinclair Corporation terminated the employment of Atanas Atanasov as Executive Vice President and Chief Financial Officer, effective immediately on May 13, 2026, after he had been on leave since February 24, 2026. Vivek Garg, the Company's Vice President, Chief Accounting Officer and Controller, has served as acting CFO since February 24, 2026. Atanasov may be eligible for severance benefits under the Company's Severance Pay Plan if conditions are met.

• · Atanasov on leave since February 24, 2026, as reported in Form 10-K filed February 27, 2026.
• · Severance Pay Plan details in Proxy Statement filed March 31, 2026.

13-05-2026

At its Annual Meeting on May 12, 2026, Forrester Research, Inc. stockholders approved the amendment and restatement of the Third Amended and Restated Employee Stock Purchase Plan, increasing available shares by 450,000, effective March 25, 2026. Stockholders also elected six directors (Robert Bennett, Neil Bradford, George F. Colony, Anthony Friscia, Corinne Munchbach, and Warren Romine), ratified PricewaterhouseCoopers LLP as independent auditors for the fiscal year ending December 31, 2026, and approved executive compensation on a non-binding basis, with all proposals passing overwhelmingly and minimal opposition or abstentions.

• · Proposal 2 (ESPP amendment): 15,623,367 For, 38,217 Against, 5,846 Abstaining.
• · Proposal 4 (executive compensation): 15,073,307 For, 156,133 Against, 437,990 Abstaining.

13-05-2026

Werner Enterprises, Inc. announced the retirement of Director Carmen A. Tapio from the Board effective May 12, 2026, with no disagreements with management or the Board. At the Annual Meeting on the same day, stockholders elected four directors (Diane K. Duren, Derek J. Leathers, Michelle D. Livingstone as Class II for three-year terms, and M. Gayle Packer as Class III for a one-year term), approved the advisory resolution on executive compensation, and ratified KPMG LLP as independent auditors for the year ending December 31, 2026. All proposals passed with strong majority support, featuring approximately 54 million 'For' votes for directors and executive compensation.

• · Stockholders of record as of March 5, 2026
• · Definitive proxy statement filed with SEC on March 31, 2026
• · Class II directors elected for three-year term expiring at 2029 Annual Meeting
• · Class III director elected for one-year term expiring at 2027 Annual Meeting

13-05-2026

Aquestive Therapeutics reported Q1 2026 total revenues of $14.4 million, up 66% YoY from $8.7 million, driven by license and royalty revenue increasing to $5.4 million from $0.8 million and manufacture and supply revenue rising 22% to $8.8 million from $7.2 million. Net loss narrowed significantly to $8.1 million ($0.07 per share) from $22.9 million ($0.24 per share), with Adjusted EBITDA loss improving to $1.7 million from $17.6 million; however, the company continues to report losses and reaffirmed full-year guidance of $46-50 million in revenue with a $30-35 million Adjusted EBITDA loss. Additionally, the company entered a $150 million debt facility with Oaktree Capital Management, saving $45 million in principal payments over three years, completed the AQST-108 Phase 1 study with no safety issues, and reaffirmed Anaphylm NDA resubmission in Q3 2026.

• · Reaffirms Anaphylm NDA resubmission in Q3 2026 following FDA Type A meeting.
• · Completed AQST-108 Phase 1 study in subjects with androgenic alopecia; no safety issues or systemic absorption observed.
• · On track for Anaphylm regulatory submissions in Canada, EU, and UK using existing data.
• · Manufacturing business remains steady; supply chain unaffected by tariffs.
• · Libervant remains tentatively approved until January 2027 due to orphan drug exclusivity.

13-05-2026

Doximity reported fiscal year 2026 revenue of $644.9 million, up 13% YoY from $570.4 million, with operating cash flow of $326.5 million up 19% YoY and free cash flow of $317.5 million up 19% YoY. However, Q4 FY2026 revenue increased only 5% YoY to $145.4 million from $138.3 million, net income declined to $19.1 million from $62.5 million (margin 13.1% vs 45.2%), and Adjusted EBITDA fell 6% to $65.8 million. The company appointed Matt Sonefeldt as new CFO and Dr. Steve Zatz as President, announced over 800,000 active prescribers, and issued FY2027 revenue guidance of $664-676 million.

• · Q1 FY2027 guidance: Revenue $151-152M, Adjusted EBITDA $68.5-69.5M
• · FY2027 guidance: Revenue $664-676M, Adjusted EBITDA $323-335M
• · Total assets declined to $1,123.7M from $1,264.3M YoY
• · Stock-based compensation FY2026: $121.6M vs $72.4M FY2025
• · Common stock repurchases FY2026: $431.7M

13-05-2026

Allogene Therapeutics reported positive interim futility analysis from the pivotal Phase 2 ALPHA3 trial, with 58.3% (7/12) of cema-cel patients achieving MRD clearance versus 16.7% (2/12) in the observation arm, alongside a favorable safety profile enabling outpatient management. Q1 2026 financials showed improved results with R&D expenses down 36% YoY to $32.0M, total operating expenses down 29% YoY to $46.1M, and net loss narrowed to $42.6M from $59.7M prior year; cash position stood at $266.9M, extended to Q1 2029 by a $200.4M public offering. ALLO-329 Phase 1 RESOLUTION trial advanced with 9 patients dosed and signs of early clinical activity.

• · Site activation and patient screening underway in South Korea and Australia for ALPHA3, expanding to over 80 sites worldwide.
• · Interim EFS analysis for ALPHA3 expected mid-2027; primary analysis mid-2028.
• · 2026 operating cash expense guidance increased to $165M from $150M; GAAP operating expenses to $225M from $210M.

13-05-2026

Vertex Pharmaceuticals held its annual shareholder meeting on May 13, 2026, electing all ten nominated directors with strong majorities (ranging from approximately 94% to 99% support). Shareholders overwhelmingly ratified Ernst & Young LLP as auditors (96% for), approved the advisory 2025 named executive officer compensation (94% for), and adopted the 2026 Stock and Option Plan (97% for); however, the shareholder proposal on action by written consent passed narrowly with 57% support.

• · Proposal 1 director elections: Bruce Sachs received highest opposition with 13,186,265 against votes (94% for)
• · Proposal 5 (written consent): 126,892,696 for vs 95,756,148 against
• · Proxy statement for 2026 Plan details filed April 2, 2026

13-05-2026

On May 12, 2026, Constantine ('Dino') Xykis resigned as CEO of Power Solutions International, Inc. (PSIX), effective immediately, after serving since April 24, 2023; he will receive previously earned 2025 bonuses totaling $1,258,074 and cash settlement of 28,334 vested SARs. The Board appointed Xun ('Kenneth') Li, current CFO since August 26, 2022, as Interim CEO with no additional cash compensation, while continuing the search for a permanent CEO. No family relationships or related-party transactions were disclosed regarding Mr. Li.

• · Mr. Li, 56, previously served as CFO of ND Paper (2020-2022), CFO of Caterpillar's machine product group (2013-2020), and held finance roles at Ford (2003-2008).
• · Mr. Li holds an MBA and MS in Accounting from University of Michigan, MS in Mechanical Engineering from University of Oklahoma, BS from Shanghai Jiao Tong University, and is a CPA in Illinois.
• · No arrangements, family relationships, or Item 404(a) transactions involving Mr. Li.

13-05-2026

Tango Therapeutics reported Q1 2026 financial results with a strong cash position of $379.8 million, providing runway into 2028, amid ongoing clinical progress including robust enrollment in vopimetostat + RAS(ON) inhibitors trials and upcoming 2026 data readouts for vopimetostat monotherapy in lung cancer and TNG456 in glioblastoma. However, collaboration revenue fell to $0 from $5.4 million YoY, G&A expenses rose 33% to $15.2 million, and net loss widened 14% to $45.5 million ($0.32 per share) from $39.9 million ($0.36 per share), despite an 8% R&D expense reduction to $33.5 million due to TNG908 discontinuation. Corporate updates include board resignations by Alexis Borisy and Kanishka Pothula, and new appointments of Matthew Gall as CFO, Yen-Ching Chua as CDOO, and Janice Kapty as SVP Corporate Strategy.

• · TNG908 clinical program discontinued, contributing to R&D expense decrease
• · Total assets increased to $435.8 million as of March 31, 2026 from $398.7 million as of December 31, 2025
• · Stockholders’ equity increased to $391.5 million as of March 31, 2026 from $346.2 million as of December 31, 2025

13-05-2026

The Hanover Insurance Group, Inc. (NYSE: THG) announced a new board-approved share repurchase authorization of $700 million for its common stock, terminating the prior program which had approximately $63 million remaining. Jeffrey M. Farber, EVP and CFO, stated this reflects confidence in earnings durability and a disciplined capital management approach balancing business investment with shareholder returns. Repurchases may occur via open market, private transactions, or Rule 10b5-1 plans, subject to market conditions.

• · Repurchases may be executed using open market transactions, privately negotiated transactions, accelerated repurchase programs, or other methods.
• · Company may establish Rule 10b5-1 trading plans for additional flexibility.
• · Filing date: May 13, 2026

13-05-2026

Allegro MicroSystems, Inc. (Nasdaq: ALGM) appointed Robert J. Willett as an independent director to its Board, effective May 13, 2026. Mr. Willett brings over two decades of experience in industrial technology and automation, including 14 years as CEO of Cognex Corporation where he scaled the business and drove organic growth. The appointment is viewed positively by Chairman Joseph Martin for adding expertise in sensors, industrial automation, and capital deployment to support Allegro's expansion in automotive, AI data centers, and robotics.

• · Mr. Willett holds a bachelor’s degree from Brown University and an MBA from Yale University.
• · Contact: jhoover@allegromicro.com

13-05-2026

Selling stockholders, affiliates of prior private equity sponsors Warburg Pincus LLC and GTCR LLC, sold 31,838,253 shares of Sotera Health Company common stock at $15.168 per share to Goldman Sachs & Co. LLC as underwriter on May 13, 2026, pursuant to an underwriting agreement dated May 11, 2026. As a result, the sponsors no longer own any common stock, leading to the termination of the November 19, 2020 Stockholders Agreement and the end of their special corporate governance rights, including board designations. The company did not issue or sell any shares and received no proceeds from the transaction.

• · Stockholders Agreement originally dated November 19, 2020, and previously filed as Exhibit 10.9 to the 2020 Annual Report.
• · Existing directors previously designated by the Sponsors are not required to resign and may serve until the end of their terms.
• · None of the Company’s executive officers participated in the sale of the Shares.

13-05-2026

Venu Holding Corp's wholly owned subsidiary, Sunset at Chattanooga, LLC, entered into a Purchase and Sale Agreement on May 8, 2026, to acquire an approximately 15-acre parcel in Chattanooga, Tennessee, for $20.0 million, with plans to develop and operate a multi-seasonal amphitheater and entertainment complex. The purchase price will be funded through Development Incentive Funding, Suite Sales Revenue from pre-selling firepit suites, and a ticket fee participation agreement with the seller. Closing is expected by December 31, 2026, but is contingent on securing satisfactory development agreements, minimum incentives, pre-sales, and an additional parcel transfer, all at the purchaser's discretion.

• · Purchaser's obligation to close contingent on conditions satisfied by six-month anniversary (November 8, 2026), including minimum tax increment financing, ticket participation fees to government entities, and structured parking facility agreement.
• · Purchase Agreement includes customary terms such as earnest money deposit, tax prorations, inspection rights, title examination, seller representations, and warranties.

13-05-2026

Myomo, Inc. appointed Joseph M. Manko Jr., Senior Principal of Horton Capital Management LLC (a significant shareholder), as a director effective May 9, 2026, expanding the board to seven members until the 2027 annual meeting. Mr. Manko brings over 25 years of experience in investment banking, private equity, and asset management, with prior roles at BZ Fund Management, Deutsche Bank, Merrill Lynch, and as a corporate finance attorney at Skadden, Arps, Slate, Meagher & Flom. The appointment aims to support Myomo's growth strategy, Success Pillars for 2026, and long-term shareholder value.

• · Mr. Manko currently serves on the boards of Safeguard Scientifics and Koru Medical Systems.
• · Mr. Manko earned B.A. and Juris Doctor from the University of Pennsylvania.
• · Myomo headquartered at 45 Blue Sky Dr., Suite 101, Burlington, MA 01803.

13-05-2026

Lincoln Educational Services Corporation's wholly-owned subsidiary, Lincoln Technical Institute, Inc., entered into a purchase and sale agreement on May 12, 2026, with Melrose Omni, LLC to acquire the real property at 8315-8317 W. North Avenue, Melrose Park, IL 60160, which it currently leases for its Melrose Park campus, for $18,800,000. Closing is anticipated on June 25, 2026, subject to customary conditions including due diligence and inspections. No financial impacts or performance metrics are disclosed in the filing.

• · Property includes building, improvements, and other personal property thereon
• · Purchase price as adjusted per agreement terms
• · Agreement filed as Exhibit 10.1

13-05-2026

Prestige Consumer Healthcare reported FY2026 revenues of $1,088.7 million, down 4.3% YoY from $1,137.8 million, and Q4 revenues of $281.6 million, down 5.0% from $296.5 million, primarily due to supply constraints for Clear Eyes® in Eye & Ear Care and shipping disruptions in the Middle East; however, free cash flow rose to $246.4 million from $243.3 million, supporting $156 million in share repurchases. The company announced a definitive agreement to acquire LaCorium Health for $150 million in cash, expected to add $40 million TTM revenue and $12 million EBITDA post-synergies. FY2027 outlook includes organic revenue growth of 1% to 3% and adjusted diluted EPS of $4.42 to $4.51.

• · North American OTC segment revenues declined due to Eye & Ear Care supply issues for Clear Eyes®.
• · International OTC segment saw flat Q4 performance with shipping disruptions in Middle East, partly offset by growth in Women’s Health and Cough & Cold.
• · FY2026 adjusted diluted EPS of $4.38 vs. $4.52 prior year.
• · Net cash from operating activities $257.6M in FY2026 vs. $251.5M prior year.
• · Leverage ratio 2.6x as of March 31, 2026.
• · LaCorium acquisition expected to close Q2 FY2027; 75% sales in Australia.
• · Upcoming Breathe Right® acquisition anticipated in June FY2027.

13-05-2026

Linkhome Holdings Inc. (Nasdaq: LHAI) announced a definitive agreement to acquire 100% of Constant Investments, Inc. d/b/a Mortgage One Group, a mortgage lender with 8 branch offices, licenses in 18 U.S. states (8 active), approximately 30 loan officers, 9 loan managers, and an $18 million warehouse line of credit. The transaction, expected to close on or before July 1, 2026 subject to customary conditions, aims to integrate Mortgage One's lending infrastructure with Linkhome's AI for enhanced mortgage origination, nationwide expansion, and acceleration of Cash Offer and Buy Before Sell programs. While anticipated synergies are highlighted, forward-looking statements note risks such as failure to close, integration issues, regulatory hurdles, and market conditions.

• · Mortgage One Group holds mortgage lending licenses in 18 U.S. states, with 8 currently active.
• · Integration planning is underway, with further updates planned post-closing.
• · Additional transaction details to be in upcoming Form 8-K.

13-05-2026

CNL Healthcare Properties, Inc. reported total revenues of $392.7 million for the year ended December 31, 2025, up 7.3% YoY from $366.0 million, driven by 7.5% growth in resident fees and services to $364.2 million and operating income rising 9.5% to $33.8 million. However, the company recorded a net loss of $8.8 million, an improvement from $14.5 million in 2024 but still negative, with real estate investment properties net declining 2.9% to $1.2 billion, total assets down 2.4% to $1.29 billion, and stockholders' equity falling 3.6% to $686.2 million. Operating cash flow improved significantly by 25% to $50.4 million amid ongoing cash distributions of $17.8 million.

• · Critical audit matter identified: Analysis of real estate assets for indicators of impairment, with net carrying value of $1.2 billion as of Dec 31, 2025.
• · Mortgages and other notes payable fully repaid to $0 from $15.8 million as of Dec 31, 2025.
• · Credit facilities increased to $563.9 million from $550.3 million as of Dec 31, 2025.
• · Cash distributions declared at $0.10240 per share for 2025, totaling $17.8 million.
• · Audited by PricewaterhouseCoopers LLP (PCAOB ID 238), serving since 2010.

13-05-2026

CEL-SCI Corporation announced the pricing of a best-efforts public offering of 6,000,000 shares of common stock at $1.20 per share, expecting gross proceeds of approximately $7.2 million before fees and expenses. The proceeds will fund continued development of Multikine, general corporate purposes, and working capital, with closing expected on May 13, 2026. ThinkEquity is the sole placement agent.

• · Registration statement on Form S-1 (File No. 333-295168) effective May 11, 2026.
• · Multikine received Orphan Drug designation from FDA for neoadjuvant therapy in head and neck squamous cell carcinoma.
• · Company operations in Vienna, Virginia, and near/in Baltimore, Maryland.

13-05-2026

Live Oak Acquisition Corp. V (SPAC) and Teamshares Inc. executed a Second Amendment to their Agreement and Plan of Merger originally dated November 14, 2025 (first amended April 1, 2026), effective May 13, 2026. The amendment primarily revises the pre-closing treatment of certain Company Preferred Stock, introducing a 'Liquidation Preference Election' for Eligible Preferred Holders of specified series (C-1, C-2, D-1, D-2, D-NV, E, E-NV), allowing conversion to Company Common Stock based on liquidation preference (greater of Original Issue Price plus dividends or standard conversion), with electing holders waiving post-closing Earnout Shares. It also makes minor conforming changes to definitions, section references, and numbering for accuracy.

• · Eligible Preferred Shares: Company Series C-1, C-2, D-1, D-2, D-NV, E, and E-NV Preferred Stock.
• · Liquidation Preference Election holders forfeit rights to Earnout Shares during post-Closing Earnout Period.
• · Scrivener's errors corrected in Section 6.3(e), including renumbering of subclauses and schedule reference.

13-05-2026

On May 11, 2026, the Compensation and Talent Development Committee of Johnson Controls International plc approved the Value Growth Incentive Program (VGI Program), a long-term incentive linking executive compensation to aggressive five-year sales and market capitalization growth goals from FY2026 to FY2030. The program grants performance-based options to key executives, including CEO Joakim Weidemanis ($10,500,000 target fair value), CFO Marc Vandiepenbeeck ($5,300,000), and CHRO Chris Scalia ($5,300,000), vesting only upon substantial outperformance and continued service. No performance shortfalls or declines are noted, as this establishes new ambitious targets beyond existing plans.

• · Performance Period: fiscal years 2026 through 2030
• · Sales Goal: specified level of net sales over trailing 12 months on measurement dates, plus specified market cap level
• · Market Cap Goal: average over 45 days prior to measurement dates
• · Grant date: May 15, 2026; exercise price equals share price on grant date
• · Vesting requires continued service; pro rata for qualifying termination, death, or disability
• · Exercise window: October 1, 2030 to September 30, 2032 (or 90 days for pro rata)
• · Program document and award agreement to be filed in Q2 FY2026 10-Q

13-05-2026

Riley Exploration Permian, Inc. held its annual stockholder meeting on May 12, 2026, where all seven director nominees were elected, the appointment of BDO USA, P.C. as auditors for 2026 was ratified with overwhelming support (17,109,342 for vs. 84,778 against), advisory approval of executive compensation passed, and the Second Amended and Restated 2021 Long Term Incentive Plan was approved, increasing shares available by 2,800,000 from 2,337,022 to 5,137,022. While director elections saw some withheld votes (e.g., 1,136,715 for Bryan H. Lawrence), and the incentive plan faced notable opposition (3,427,837 against), all proposals passed. No financial declines reported.

• · Proxy statement filed April 10, 2026
• · Broker non-votes: 1,832,263 shares across most proposals
• · Auditor ratification abstentions: 14,266 shares
• · Executive compensation: 376,548 votes against, 24,821 abstentions
• · Highest withheld director votes: Bryan H. Lawrence (1,136,715)

13-05-2026

At the PPL Corporation 2026 Annual Meeting of Shareowners on May 13, 2026, shareholders elected all nine director nominees with majority support, though Phoebe A. Wood faced the highest opposition at 17,856,806 votes against. Shareowners also approved the Second Amended and Restated 2012 Stock Incentive Plan (582,471,858 for vs. 16,548,521 against), provided advisory approval for 2025 named executive officer compensation, and ratified Deloitte & Touche LLP as the independent auditor for the year ending December 31, 2026, with unanimous broker participation. All proposals passed decisively, with consistent broker non-votes of 69,012,081 across most items.

• · Director votes - Arthur P. Beattie: 597,406,687 For, 2,708,599 Against; Raja Rajamannar: 591,713,120 For, 8,355,246 Against
• · Craig A. Rogerson: 585,640,565 For, 14,497,403 Against; Keith H. Williamson: 586,715,596 For, 13,385,229 Against
• · Executive compensation advisory: 580,083,934 For, 18,747,637 Against; Auditor ratification: 662,634,703 For, 6,313,167 Against (no broker non-votes)

13-05-2026

On May 12, 2026, the Board of Directors of FiEE, Inc., upon recommendation of the Compensation Committee, granted 143,561 restricted stock units (RSUs) each to Chief Executive Officer and President Li Wai Chung and Chief Financial Officer Cao Yu under the FiEE, Inc. 2025 Equity Incentive Plan. Each RSU represents a contingent right to one share of common stock, $0.01 par value, vesting 30% on the first anniversary, 30% on the second, and 40% on the third anniversary, subject to continued employment. No other performance metrics or financial impacts were disclosed.

• · RSUs subject to terms of the Plan and Exhibit 10.1 (Form of Restricted Stock Unit Award Agreement).
• · Common stock: $0.01 par value per share, traded as FIEE on The Nasdaq Capital Market.

13-05-2026

Allegiant Travel Company (ALGT) completed its acquisition of Sun Country Airlines Holdings, Inc. (SNCY) on May 13, 2026, forming a leading U.S. leisure-focused airline with a combined fleet of 195 aircraft serving nearly 175 cities, 22 million annual customers, and more than 650 routes. The transaction is expected to deliver approximately $140 million in annual synergies within three years, driven by scale efficiencies, fleet optimization, and procurement benefits, and to be accretive to earnings per share in the first full year post-closing. Both airlines will operate separately in the near term with no immediate changes to customer reservations, flight schedules, or frontline roles, though integration risks including potential delays, higher costs, and operational challenges are highlighted.

• · Sun Country common stock ceased trading on NASDAQ post-closing.
• · Minneapolis-St. Paul to remain an important operating center.
• · Sun Country’s charter contracts include casinos, Major League Soccer, collegiate sports teams, and Department of Defense.
• · All existing collective bargaining agreements remain in place.

13-05-2026

Akamai Technologies, Inc. filed an 8-K on May 13, 2026, including Exhibit 3.1, which is the Amended and Restated Certificate of Incorporation amending the prior version filed on May 16, 2024. The certificate authorizes 700,000,000 shares of common stock ($0.01 par value) and 5,000,000 shares of preferred stock ($0.01 par value), with standard provisions for voting (one vote per common share, no cumulative voting), dividends, liquidation rights, board authority on bylaws, director/officer liability limitations, and indemnification policies. No financial performance metrics, changes, or operational impacts are disclosed.

• · Original Certificate of Incorporation filed August 20, 1998.
• · Series A Junior Participating Preferred Stock Certificate of Designations filed September 10, 2002.
• · Registered office: 1209 Orange Street, City of Wilmington, 19801, County of New Castle, Delaware.

13-05-2026

At the May 12, 2026 annual meeting of stockholders, with 83.77% quorum of 31,945,516 outstanding shares, Alto Neuroscience, Inc. stockholders elected Raymond Sanchez, M.D. and Gwill York as Class II directors until 2029 and ratified Deloitte & Touche LLP as independent auditors for the fiscal year ending December 31, 2026. However, the amendment to the 2024 Equity Incentive Plan failed with more votes against (12,205,864) than for (10,838,509), while the amendment to the 2024 Employee Stock Purchase Plan passed narrowly (11,946,818 for vs. 11,097,535 against).

• · Proposal 1 votes - Raymond Sanchez, M.D.: 23,133,161 For, 31,432 Withheld; Gwill York: 12,385,501 For, 10,779,092 Withheld.
• · Proposal 2 votes: 26,727,215 For, 23,440 Against, 12,154 Abstentions.
• · Proposal 3 votes: 10,838,509 For, 12,205,864 Against, 120,220 Abstentions.
• · Proposal 4 votes: 11,946,818 For, 11,097,535 Against, 120,240 Abstentions.
• · Board adopted A&R 2024 ESPP on March 16, 2026; Proxy Statement filed March 26, 2026.

13-05-2026

NusaTrip Incorporated (NUTR) announced the resignation of Albert Nicolas as Chief Operating Officer, effective May 13, 2026, which was not due to any disagreement with the company. The company appointed Ade Irawan as the new COO on the same date, entering into a 3-year employment agreement with an annual base salary of $26,000 and eligibility for the company bonus plan. Mr. Irawan brings over 17 years of experience in aviation, travel operations, and digital travel technology, having held progressively senior roles at the company since 2019.

• · Albert Nicolas’s resignation was not the result of any disagreement with the Company, its management, operations, policies or practices.
• · Ade Irawan previously held roles at the Company: Quality Monitoring & Trainer (Nov 2019-Nov 2022), Business Development (Dec 2022-Sep 2025), Commercial Manager (Sep 2025-present).
• · No family relationships between Ade Irawan and any director or executive officer; no direct or indirect material interest in transactions under Item 404(a) of Regulation S-K.
• · Employment agreement term: 3 years.

13-05-2026

Newell Brands Inc. held its Annual Meeting of Stockholders on May 7, 2026, where all eight director nominees were elected with majority support ranging from 87% (Patrick D. Campbell) to 98% (Gerardo I. Lopez, Christopher H. Peterson, Anthony Terry). Stockholders ratified PricewaterhouseCoopers LLP as auditors (99% support), approved Say-On-Pay (78% support despite 22% opposition), and approved the 2026 Incentive Plan (93% support). Of 424,927,772 shares outstanding as of the March 12, 2026 record date, 368,135,426 shares were voted, with 41,561,938 broker non-votes.

• · Director votes - Bridget Ryan Berman: 310,789,046 For, 15,433,058 Against, 351,384 Abstain
• · Director votes - Patrick D. Campbell: 283,377,489 For, 42,822,754 Against, 373,245 Abstain
• · Director votes - James P. Keane: 302,088,999 For, 24,084,176 Against, 400,313 Abstain
• · Director votes - Gerardo I. Lopez: 320,436,005 For, 5,707,674 Against, 429,809 Abstain
• · Director votes - Christopher H. Peterson: 321,807,657 For, 4,437,197 Against, 328,634 Abstain
• · Director votes - Gary H. Pilnick: 302,428,045 For, 23,717,278 Against, 428,165 Abstain
• · Director votes - Stephanie P. Stahl: 299,906,682 For, 26,222,825 Against, 443,981 Abstain
• · Director votes - Anthony Terry: 321,216,034 For, 4,883,089 Against, 474,365 Abstain
• · Auditor ratification: 363,199,115 For, 4,359,352 Against, 576,959 Abstain
• · Say-On-Pay: 254,464,829 For, 71,068,404 Against, 1,040,255 Abstain
• · 2026 Incentive Plan: 305,206,680 For, 20,662,767 Against, 704,041 Abstain
• · Proxy Statement filed March 26, 2026

13-05-2026

Sun Country Airlines Holdings, Inc. filed an 8-K on May 13, 2026, including an Amended and Restated Certificate of Incorporation that drastically reduces authorized common stock to 100 shares with a $0.01 par value each. This accompanies Items 1.02 (Material Agreement Termination), 2.01 (Completion of Acquisition or Disposition), 3.01/3.03 (Delisting/Material Notices), and 5.01-5.03 (Changes in Control/Directors/Officers), indicating a major restructuring likely tied to an acquisition. No operational or financial performance metrics are provided.

• · Registered office: 850 New Burton Road, Suite 201, Dover, County of Kent, 19904, Delaware.
• · Standard provisions include board management of affairs, director liability limitations under DGCL Section 102(b)(7), and stockholder meeting flexibility.

13-05-2026

Outlook Therapeutics, Inc. entered into an At-The-Market Offering Agreement with H.C. Wainwright & Co., LLC on May 13, 2026, to issue and sell shares of its common stock ($0.01 par value per share) from time to time through the Manager as exclusive sales agent. Sales will be made on Trading Days at market prices, up to the Maximum Amount limited by the Registration Statement (File No. 333-278340 on Form S-3), authorized but unissued shares, and Form S-3 eligibility requirements. The Manager receives a 3.0% broker fee on gross sales proceeds, with no fixed offering size or proceeds specified.

• · Registration Statement File Number: 333-278340 on Form S-3.
• · Settlement Date: T+1 Trading Day following sales (10:00 a.m. New York City time).
• · Sales via Sales Notice specifying daily maximum shares and minimum price.
• · Manager has no obligation to purchase shares as principal except via separate Terms Agreement.

13-05-2026

NexPoint Real Estate Finance Operating Partnership, L.P. entered into a secured $20.0 million revolving credit agreement with VineBrook Homes Operating Partnership, L.P. on May 7, 2026, at 9.75% per annum interest, maturing May 7, 2028 with two one-year extension options. The facility can increase to $30.0 million subject to approval and includes a 1.00% origination fee and 0.50% extension fee. No performance declines or flat metrics reported.

• · Secured by properties that subsidiaries of the Borrower acquire with loan proceeds.
• · Amounts owed may be prepaid at any time without premium or penalty.
• · Contains customary representations, warranties, affirmative and negative covenants, and events of default, including maximum debt to capital ratio, minimum net asset value, and minimum net operating income.

13-05-2026

A&B Aerospace, Inc., the target in a potential sale transaction referenced in PMGC Holdings Inc.'s (ELAB) 8-K filing, reported nine-month revenue growth of 12.8% YoY to $3,607,404 and swung to net income of $343,903 from a prior-year loss of $108,061, with operating cash flow rising to $349,252 from $134,235. Three-month revenue surged 25.5% YoY to $1,274,503, driving net income of $123,492 versus a $313,582 loss. However, the nine-month period included a $695,763 inventory impairment charge, and property and equipment net declined to $463,772 from $543,627.

• · Net working capital of $1,447,000 as of Feb 28, 2026 with current ratio of 3.9:1
• · Investments at fair value $344,336 as of Feb 28, 2026 versus $178,657 at May 31, 2025
• · Total liabilities decreased to $497,497 from $520,329
• · Stockholders’ equity $1,911,116 as of Feb 28, 2026

13-05-2026

Aquaron Acquisition Corp. entered into Amendment No. 4 to its Investment Management Trust Agreement with Continental Stock Transfer & Trust Company, dated May 7, 2026, extending the Trust Account liquidation deadline from May 6, 2024 (as previously amended) to the later of May 6, 2027 or as provided in the Company's Amended and Restated Certificate of Incorporation. The Trust Account holds $54,984,377 from IPO and Private Placement Units proceeds. The amendment was approved by the requisite stockholder vote holding at least 50% of Common Stock.

• · Previous amendments to Trust Agreement: June 29, 2023 (No. 1), April 30, 2024 (No. 2), May 6, 2025 (No. 3)
• · Original Trust Agreement dated October 3, 2022
• · Stockholder approval threshold: affirmative vote of holders of at least 50% of Common Stock present or represented

13-05-2026

Tempus AI, Inc. (TEM) announced a proposed private placement of $350.0 million aggregate principal amount of Convertible Senior Notes due 2032, with an option for initial purchasers to buy up to an additional $52.5 million, to repay in full $307.7 million of outstanding loans under senior secured credit facilities plus accrued interest and fees, thereby reducing interest expense and enhancing financial flexibility. Net proceeds will also fund capped call transactions to reduce potential dilution upon conversion and support general corporate purposes including acquisitions and working capital. While the offering aims to optimize capital structure, related hedging activities by counterparties may impact the market price of Class A common stock or Notes.

• · Notes to be offered pursuant to Rule 144A to qualified institutional buyers.
• · Notes mature on May 15, 2032; interest payable semiannually in arrears.
• · Upon conversion, Tempus may settle in cash, Class A common stock (par value $0.0001), or combination.
• · Capped call transactions to cover shares underlying the Notes, subject to adjustments.
• · Announcement date: May 7, 2026; SEC filing date: May 13, 2026.

13-05-2026

GP-Act III Acquisition Corp. entered into Non-Redemption Agreements on May 11, 2026, with investors holding 8,074,387 Class A ordinary shares, committing them not to redeem shares and to vote in favor of extending the business combination deadline from May 13, 2026, to November 13, 2026 (Extension Amendment Proposal) and amending the trust agreement accordingly (Trust Amendment Proposal). In exchange, the Sponsor (GP-Act III Sponsor LLC) will transfer 403,720 Class A ordinary shares to these investors post-business combination closing. These agreements aim to boost approval chances at the upcoming extraordinary general meeting and preserve more funds in the trust account.

• · Proxy statement filed with SEC on March 30, 2026; record date for meeting March 24, 2026
• · Investment Management Trust Agreement dated May 8, 2024
• · Non-Redemption Agreements terminate upon failure of proposals approval, fulfillment of obligations, liquidation, mutual agreement, or investor breach
• · Company may enter additional similar non-redemption agreements

13-05-2026

Armata Pharmaceuticals reported Q1 2026 financial results with grant revenue up 61% YoY to $0.8M, but R&D expenses rose 13% to $6.1M, G&A up 6% to $3.5M, operating loss widened to $8.8M from $8.2M, and net loss ballooned to $115.3M (vs $6.5M) due to a $101M unfavorable change in fair value of convertible loan. The company entered a $25M secured credit agreement with Innoviva maturing 2029 to fund AP-SA02 Phase 3 study in H2 2026, received FDA Fast Track and QIDP designations for AP-SA02, and appointed Dr. Daniel Gilmer to its Board. Cash and equivalents fell to $4.8M as of March 31, 2026, from $8.7M at December 31, 2025.

• · Amendments to prior credit agreements extended maturities to June 1, 2027, with warrant extensions to January 26, 2031.
• · Net cash used in operating activities $5.8M in Q1 2026 vs $7.6M in Q1 2025.
• · Published paper on phage P7-1 structure in Communications Biology; presented at Bacteriophage Therapy Summit March 24-26, 2026.

13-05-2026

Zenas BioPharma reported Q1 2026 financial results with cash, cash equivalents, and investments of $718.5 million, bolstered by $419.0 million in gross proceeds from financings extending runway into Q2 2029, and positive Phase 3 INDIGO trial results for obexelimab demonstrating a 56% reduction in IgG4-RD flare risk. However, R&D expenses increased 73% YoY to $60.4 million, G&A expenses rose 36% to $16.9 million, and net loss widened to $81.0 million from $33.6 million due to higher clinical, manufacturing, and personnel costs. Corporate progress includes completed enrollment in the Phase 2 SunStone SLE trial with topline data expected Q4 2026 and first dosing in ZB021 Phase 1 trial.

• · Obexelimab BLA submission to FDA targeted for Q2 2026; MAA to EMA in H2 2026
• · INDIGO trial data oral presentation at EULAR 2026 Congress on June 4, 2026
• · ZB021 Phase 1 initial data expected year-end 2026; POC trial in psoriasis planned for 2027
• · ZB022 and ZB014 Phase 1 studies expected in 2027 subject to oIND results
• · $45.0 million aggregate gross proceeds from underwriters’ full exercise of over-allotment options
• · Potential $75 million milestone from Royalty Pharma and $75 million debt draw upon FDA approval of obexelimab for IgG4-RD

13-05-2026

Starlink AI Acquisition Corporation, a Cayman Islands-based blank check company (SPAC), priced its initial public offering of 10,000,000 units at $10.00 per unit, raising $100 Million. Units are expected to begin trading on the NYSE under ticker OTAIU on May 8, 2026, with closing anticipated on May 11, 2026, subject to customary conditions. A.G.P./Alliance Global Partners serves as the sole book-running manager and has a 45-day option to purchase up to 1,500,000 additional units for over-allotments.

• · Each unit consists of one ordinary share and one right to receive one-fourth of one ordinary share upon consummation of an initial business combination.
• · Registration statement on Form S-1 (File No. 333-292878) declared effective by SEC on May 7, 2026.
• · Post-separation trading: ordinary shares as OTAI, rights as OTAIR on NYSE.
• · Company targets merger, share exchange, asset acquisition, or similar business combination without industry limitation.

13-05-2026

Anteris Technologies Global Corp. appointed Ms. Susan Knight as a Class I Director (term expiring at 2028 annual meeting) and Mr. Stephen Denaro as a Class II Director (term expiring at 2026 annual meeting) effective May 11, 2026 (May 12 in Australia), with Ms. Knight joining the Audit and Risk Committee. Ms. Knight brings extensive CFO and board experience from Surmodics, Inc., MTS Systems Corporation, and Honeywell, Inc., while Mr. Denaro rejoins with deep company knowledge. Compensation includes an initial $250,000 RSU grant for Ms. Knight, $125,000 annual RSUs for both, and AUD $57,645 annual fee for Mr. Denaro's subsidiary secretary roles.

• · Indemnification agreements entered with Ms. Knight and Mr. Denaro effective May 11, 2026.
• · Ms. Knight's RSU grant subject to stockholder approval per Australian Securities Exchange rules.
• · Mr. Denaro serves as Company Secretary for certain Australian subsidiary entities.

13-05-2026

Eos Energy Enterprises reported Q1 2026 revenue of $57.0 million, a 445% YoY increase driven by higher cube deliveries and automation, alongside record quarterly production and shipments, a $24.3 billion commercial pipeline up 56% YoY, and $644.6 million orders backlog; however, it recorded a gross loss of $44.4 million and adjusted EBITDA loss of $68.0 million despite significant margin improvements. The company announced the formation of Frontier Power USA with Cerberus, anchored by a $100 million equity commitment from Cerberus and ~$150 million from Eos, and entered a 2 GWh firm capacity reservation agreement, while reaffirming 2026 revenue guidance of $300 million to $400 million. Total cash was $472.4 million as of March 31, 2026.

• · Completed Factory Acceptance Testing for second battery line; initial production expected by end of Q2 2026.
• · Expanded Southeast utility project from 4-hour to 10-hour discharge with DawnOS upgrade.
• · Entered Joint Development Agreement with TURBINE-X Energy Inc. targeting up to 2 GWh deployments.
• · Conference call scheduled for May 13, 2026, at 8:30 a.m. ET.

13-05-2026

AptarGroup, Inc. appointed Aditya J. Gandhi as Vice President and Chief Accounting Officer effective June 8, 2026, succeeding Daniel Ackerman, who transitioned to another leadership role within the Aptar Finance organization. Mr. Gandhi, aged 46, brings extensive experience as Chief Accounting Officer at Sonoco Products Company and prior roles at WestRock, General Electric, and Deloitte. Compensation includes a $105,000 sign-on bonus and a one-time equity award valued at $715,000 ($305,000 in restricted stock units and $410,000 in performance-based restricted stock units).

• · Offer letter dated May 10, 2026.
• · No arrangements or understandings with other persons for appointment.
• · No family relationships with directors or executive officers.
• · No direct or indirect interest in transactions requiring disclosure under Item 404(a) of Regulation S-K.
• · Mr. Gandhi holds a Bachelor of Commerce in Accounting, Finance and Economics from University of Mumbai, CPA, and Chartered Accountant with The Institute of Chartered Accountants of India.

13-05-2026

Rent the Runway, Inc. announced that Co-Founder Jennifer Hyman will step down as CEO, President, and Board member effective May 15, 2026, transitioning to an advisor role through January 2027. Board member Teri Bariquit, a 37-year retail veteran and former Chief Merchandising Officer at Nordstrom, was appointed Interim CEO and President to lead alongside the Executive Leadership Team during the search for a permanent CEO. The company reaffirmed its full year 2026 financial guidance, citing strong momentum in AI investments, online marketplace, media, and B2B platforms with no reported declines.

• · Company founded in 2009; IPO completed in 2021
• · Teri Bariquit served as Chief Merchandising Officer at Nordstrom from 2019 to 2023
• · Bariquit joined Rent the Runway Board in October 2025
• · Guidance reaffirmed from April 14, 2026 presentation
• · Annual Report on Form 10-K for year ended January 31, 2026

13-05-2026

Future Vision II Acquisition Corp., a SPAC, entered into an unsecured promissory note for $191,475 with HWei Super Speed Co. Ltd. dated May 8, 2026, to deposit funds into its trust account for a one-month extension of the Business Combination deadline from May 13, 2026, to June 13, 2026. The interest-free note is convertible into units at $10.00 per unit upon Business Combination consummation, subject to a $1,500,000 aggregate limit for similar loans. No personal liability for officers or directors, and the note is forgiven if no Business Combination occurs by the extended deadline.

• · Payee waives all claims to the Trust Account; note forgiven upon liquidation if no Business Combination
• · Governed by New York law
• · No interest accrues; payable on consummation of Business Combination or conversion